The issue, which some experts argue is inevitable, occurs when drugmakers stamp out pills on the same machine that is used to stamp out a different pill.
Drug cross-contamination is rampant, but the amount of cross-contaminated drugs that have been prescribed to Americans remains unclear because drugmakers largely handle the matter themselves, supervisors are often lax on cross-contamination guidelines and employees are fallible, current and former FDA inspectors told Bloomberg.
The FDA determines how often it will inspect drug manufacturing plants based on its calculation of risk associated with each facility, so many plants go years without inspections.
Comprehensive independent testing is difficult to achieve because inspectors would need to know which substances they’re looking for, and drugmakers don’t disclose which products they make at which factories.
When a routine test reveals an inappropriate substance in a drug, drugmakers often don’t test them for cross-contamination. If they say their cleaning policies are rigorous and they haven’t recorded elevated levels of drug substance left behind, they deem cross-contamination testing to be unnecessary, current and former FDA inspectors told Bloomberg.
The inspectors also said the FDA has not routinely collected samples of drugs for cross-contamination testing after red flags are found.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
